Third Harmonic Bio Inc (THRD) Return on Investment ROI from the first quarter of 2025 to first quarter of 2024 and for the year 2025, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Third Harmonic Bio Inc   (NASDAQ: THRD)


Third Harmonic Bio Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Third Harmonic Bio Inc's ROI in the first quarter of 2025?
Third Harmonic Bio Inc achieved a return on average invested assets (ROI) of 19.1 % in its first quarter of 2025 a new company high.

ROI has improved compared to 16.37% in the fourth quarter of 2024, due to net income growth.

Within the Healthcare sector 58 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2025 quarter, so far to 336, from total ROI ranking in the fourth quarter of 2024 at 489.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Investment Change TTM 2.04 % -0.52 % -3.67 % -7.32 % -5.64 %
Y / Y Net Income Change TTM 80.59 % 47.51 % 63.41 % 96.71 % 225.76 %
Investment (TTM) in Millions 275 287 297 260 267
Return On Investment (TTM) 19.1 % 16.37 % 14.31 % 12.19 % 10.79 %
THRD's Overall Ranking # 336 # 489 # 543 # 670 # 762
Seq. Investment Change TTM 0.74 % 1.39 % 1.96 % -2.01 % -1.79 %
Seq. Net Income Change TTM 17.55 % 16 % 19.72 % 10.63 % -3.99 %
Net Income (TTM) in Millions 53 45 39 33 30

THRD Company Profile >> Back to THRD Roi Comparisons >> See Annual THRD Return On Investment



Return On Investment THRD's Ranking
Within: No.
Industry # 27
Sector # 59
Overall # 336

Return On Investment Statistics
High Average Low
19.1 %
9.72 %
-1.55 %
(Mar 31 2025)   (Dec 31 2022)







Financial Statements
Third Harmonic Bio Inc's I. Quarter Investments $ 275 Millions THRD's Balance sheet
Third Harmonic Bio Inc's I. Quarter Income $ 16 Millions Quarterly THRD's Income Statement
THRD's Income by Division See THRD's Income by Division


THRD Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022

Total Investments in Millions 287 272 293 0 0
Y / Y Investment Growth 5.58 % -7.07 % - - -
Net Income in Millions 45 31 35 0 0
Y / Y Net Income Growth 47.51 % -12.32 % - - -
Annual Return On Investment 15.82 % 11.32 % 12 % - -


Annual Roi Comment
In the fiscal year 2024 ROI improved to 15.82 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
THRD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for THRD's Competitors
Subscribers only: Roi for Third Harmonic Bio Inc's Suppliers
Subscribers only: Return On Investment for THRD's Customers

Other Ratios
THRD's Roa THRD's Inventory Turnover Ratio THRD's Growth Rates THRD's Dividend Statistics
THRD's Profitability Ratios THRD's Asset Turnover Ratio THRD's Dividend Growth
THRD's Roe THRD's Valuation Ratios THRD's Financial Strength Ratios THRD's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector ROI
Bluebird Bio Inc   52.44 %
Seres Therapeutics Inc   52.22 %
Pharmacyte Biotech Inc   48.77 %
Agios Pharmaceuticals Inc   48.46 %
Dariohealth Corp   44.97 %
Sbc Medical Group Holdings Incorporated  41.74 %
Champions Oncology Inc   41.16 %
Ptc Therapeutics inc   40.79 %
Rigel Pharmaceuticals Inc  39.96 %
Mettler toledo International Inc   39.75 %
Idexx Laboratories Inc  39.40 %
Edwards Lifesciences Corporation  38.53 %
Puma Biotechnology Inc   34.10 %
Hims and Hers Health Inc   34.04 %
Medpace Holdings Inc   33.49 %
Acadia Pharmaceuticals Inc   32.33 %
Nutriband Inc   30.51 %
Carlisle Companies Incorporated  29.62 %
Catalyst Pharmaceuticals Inc   28.11 %
Nrc Health  26.31 %
Whitehawk Therapeutics Inc   26.03 %
Halozyme Therapeutics Inc   24.84 %
Siga Technologies Inc  24.48 %
Lifevantage Corp  22.87 %
Eli Lilly And Company  22.61 %
Iradimed Corporation  22.50 %
Pro dex Inc   22.32 %
Biomx Inc  21.77 %
Merck and Co Inc   21.45 %
Alkermes Plc   21.09 %

Date modified: 2026-09-08T15:11:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.